Patent ID: 8092803
Filing Date: 2012-01-10
Classification: A61K,A61M,A61P,C07K

Abstract:
1. A stable liquid ophthalmic formulation of a vascular endothelial growth factor (VEGF) antagonist, comprising: (a) between 50 mg/ml to about 10 mg/ml of a VEGF antagonist comprising amino acids 27-475 of SEQ ID NO:4; (b) about 0.03% to about 0.1% polysorbate; (c) about 5-40 mM of sodium phosphate buffer, pH of about 5.8 to about 7.0; and (d) either: wherein at least 99% of the VEGF antagonist is present in native conformation following storage at 5° C. for 2 months as measured by size exclusion chromatography.